Viral Immunity: Basic Mechanisms and Therapeutic Applications
joint with Respiratory Viruses: New Frontiers
Scientific Organizers: Katherine Kedzierska and Paul G. Thomas
Date: January 17 - 20, 2022
Location: Keystone Resort, Keystone, CO, USA
For important information on the coronavirus, please click here
Viruses infect millions annually, causing severe illness and threatening global public health, as exemplified by the recent SARS-CoV-2 pandemic. Limiting the impact of viral infection requires a multi-layered understanding of viral immunity, from basic research on viral recognition and host immune response, to the clinical applications of novel antiviral and host-targeted therapies and vaccines. Despite recent advances, the mechanisms of both rapid host recovery as well as severe and fatal disease outcomes, are far from clear. This Keystone Symposia conference will cover a wide range of topics in viral immunity including innate immunity and inflammation, adaptive T and B cell immunity, novel vaccine development, human immunology across anatomical sites, and innovative computational analyses. Animal models will be examined alongside human and clinical studies, and multi-disciplinary integration will enhance perspectives. A key outcome will be fostering collaborations across different approaches such as viral models and host systems, and across different communities from academia to government to industry. The overall objective of this conference is to provide a unique opportunity for cross-disciplinary interaction and knowledge exchange. Joint efforts in understanding viral immunity are needed for the rational design and development of immunotherapies and vaccines towards seasonal, emerging, and re-emerging viruses.
Scholarship Deadline: October 6 2021 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies
Registered attendees of one meeting in a joint pair may participate in sessions of the other, pending space availability.
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI154971-01
Funding for this conference was made possible (in part) by 1R13AI154971-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.